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STUDY PROTOCOL Open Access
A randomized controlled trial testing a
hyaluronic acid spacer injection for skin
toxicity reduction of brachytherapy
accelerated partial breast irradiation (APBI):
a study protocol
Gerson M. Struik1,2* , Jeremy Godart2, Gerda M. Verduijn2, Inger-Karine Kolkman-Deurloo2, Kim C. de Vries2,
Raymond de Boer2, Linetta B. Koppert3, Erwin Birnie4,5, Ali Ghandi6, Taco M. Klem1 and Jean-Philippe Pignol2,7
Abstract
Background: Accelerated partial breast irradiation (APBI) is a treatment option for selected early stage breast cancer
patients. Some APBI techniques lead to skin toxicity with the skin dose as main risk factor. We hypothesize that a
spacer injected between the skin and target volume reduces the skin dose and subsequent toxicity in permanent
breast seed implant (PBSI) patients.
Methods: In this parallel-group, single-center, randomized controlled trial, the effect of a subcutaneous spacer injection
on skin toxicity among patients treated with PBSI is tested. Eligibility for participation is derived from international
guidelines for suitable patients for partial breast radiotherapy, e.g. women aged ≥ 50 years with a histologically proven
non-lobular breast carcinoma and/or ductal carcinoma in situ (DCIS), tumor size ≤ 3 cm, node-negative, and PBSI
technically feasible. Among exclusion criteria are neoadjuvant chemotherapy, lymphovascular invasion, and allergy for
hyaluronic acid. For the patients allocated to receive spacer, after the PBSI procedure, 4–10 cc of biodegradable
hyaluronic acid (Barrigel™, Palette Life Sciences, Santa Barbara, CA, USA or Restylane SubQ®, Galderma Benelux, Breda,
the Netherlands) is injected directly under the skin using ultrasound guidance to create an extra 0.5–1 cm space
between the treatment volume and the skin. The primary outcome is the rate of telangiectasia at two years, blindly
assessed using Bentzen’s 4-point scale. Secondary outcomes include: local recurrence; disease-free and overall survival
rates; adverse events (pain, redness, skin/subcutaneous induration, radiation dermatitis, pigmentation, surgical site
infection); skin dose; cosmetic and functional results; and health-related quality of life.
A Fisher’s exact test will be used to test differences between groups on the primary outcome.
Previous studies found 22.4% telangiectasia at two years. We expect the use of a spacer could reduce the occurrence
of telangiectasia to 7.7%. A sample size of 230 patients will allow for a 10% lost to follow-up rate.
(Continued on next page)
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Discussion: In this study, the effect of a subcutaneous spacer injection on the skin dose, late skin toxicity, and cosmetic
outcome is tested in patients treated with PBSI in the setting of breast-conserving therapy. Our results will be relevant for
most forms of breast brachytherapy as well as robotic radiosurgery, as skin spacers could protect the skin with these
other techniques.
Trial registration: Netherlands Trial Register, NTR6549. Registered on 27 June 2017.
Keywords: Breast neoplasms, Partial breast irradiation, Brachytherapy, Permanent breast seeds implant, Skin toxicity
reduction, Telangiectasia, Spacer, Hyaluronic acid
Background
Breast cancer is increasingly diagnosed at an early stage
[1, 2]; for that stage, breast-conserving therapy, which
includes wide local excision and radiotherapy, is equiva-
lent to mastectomy in terms of local control and overall
survival [3, 4]. These oncological outcomes are excellent
in early-stage breast cancer patients [2]. Hence, radiother-
apy essentially provides a cosmetic and quality-of-life
benefit over mastectomy [5]. Since local recurrences usu-
ally occur close to the primary tumor [6], the concept of
accelerated partial breast irradiation (APBI) was intro-
duced [7] to both reduce the amount of breast tissue irra-
diated and enable faster treatment. For well-selected
patients, APBI has been tested and validated through large
randomized clinical trials (RCT), using either brachyther-
apy [8–11], external 3D conformal radiotherapy [12, 13],
or intraoperative radiotherapy [14, 15].
Brachytherapy has been the most evaluated technique
and recent advances beyond multicatheter implantation
include balloon or strut brachytherapy as well as perman-
ent breast seed implants (PBSI) [16, 17]. Brachytherapy is
generally well tolerated and reported long-term toxicities
are acceptable. A lower incidence of low-grade acute skin
toxicity for APBI, 21% vs 86% for whole breast radiother-
apy (p < 0.001) has been reported for the GEC-ESTRO
trial [18]. Regarding late side effects at five-year follow-up,
lower rates of severe grade 2–3 skin, 6.9% vs 10.7%, and
similar rates of subcutaneous side effects, 12.0% vs 9.7%,
were found in this study [19]. On the other hand, in a
retrospective analysis of 1034 breast patients treated at
The Ohio State University including 31% treated with a
balloon applicator, Wobb reported more seroma grade 2
or higher (14.4% vs 2.9%, p < 0.001), more painful fat ne-
crosis (10.2% vs 3.6%, p < 0.001), and more telangiectasia
grade 2 or higher (12.3% vs 2.1%, p < 0.001) for APBI com-
pared to whole breast radiotherapy [20]. Among those
permanent side effects, increased painful seroma is almost
exclusively due to balloon applicator, fat-necrosis can be
due to multiple factors, while telangiectasia is almost
exclusively due to an excess of dose to the skin. This
makes telangiectasia a specific marker of radiation toxi-
city [21, 22]. Telangiectasia corresponds to the dilation
of an abnormal neo-vasculature in the skin following
the destruction of normal capillaries by the radiation treat-
ment, resulting in visible vessels [23]. Although rates are
lower than with whole breast irradiation, in breast brachy-
therapy 10–27% [9, 19, 24] of the patients develop some
grade of telangiectasia. The majority of lesions are grade 1
(< 1 cm2) in breast radiotherapy studies reporting on late
skin toxicity [9, 25, 26]. The onset of telangiectasia is from
six months to 10 years after radiotherapy delivery [23];
however, rates of telangiectasia peak at two years with
PBSI. Although permanent in most cases, some authors
report disappearing of the telangiectasia with longer
follow-up [9, 27]. Nevertheless, if present, telangiectasia
can remind patients of their cancer similar to a surgical
scar and have a direct negative impact on the cosmetic
outcomes [9, 26].
Several authors recommend keeping a distance of at
least 5 mm between the planning target volume (PTV)
and the skin [28, 29] and limiting the maximum skin
dose to 70% [8]. However, such constraints are not
always achievable. A simple solution would be the use of
a spacer material injected subcutaneously to move the
skin out of the high dose region [21].
In this manuscript, we report the protocol of a RCT in-
vestigating the clinical benefit of a subcutaneous spacer
injection on the skin dose, late skin toxicity, and cosmetic
outcome in patients treated with low dose rate (LDR) seed
brachytherapy. For this study, the breast skin is considered
as a critical structure for the radiotherapy and the clinical
outcomes are measured using a breakdown of traditional
skin toxicity scales in order to capture the toxicity that is
specific to radiotherapy [9, 21, 23, 30].
Methods/design
Aim and design
We propose a parallel-group RCT comparing the occur-
rence of telangiectasia at two years in PBSI patients with
or without a subcutaneous spacer injection. Allocation
ratio is 1:1 and the trial is designed to test the superiority
of the intervention. The primary hypothesis for the trial
assumes that an injected hyaluronic acid spacer will
reduce skin dose of PBSI and eventually the rate of tel-
angiectasia at two years, compared to patients undergoing
PBSI without spacer. As the intervention is applied when
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the patient is sedated, a placebo injection as comparator
was deemed unnecessary. The methods section is
described according to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
2013 checklist (see Additional file 1).
Eligible patients will be recruited at hospitals referring
patients after breast-conserving surgery for adjuvant
radiotherapy at the Erasmus MC Cancer Institute, a
large University hospital in Rotterdam, where the PBSI
technique can be performed in the Netherlands.
Eligibility and exclusion criteria
Eligibility criteria were derived from international guidelines
[31, 32] for suitable patients for partial breast radiotherapy.
Eligible patients are females aged ≥ 50 years with a con-
firmed histological diagnosis of invasive ductal carcinoma
(IDC) and/or papillary, tubular, cribriform or medullar
carcinoma and/or ductal carcinoma in situ (DCIS), after
breast-conserving surgery with axillary node dissection
(with a minimum of six nodes sampled) or sentinel lymph
node biopsy. The maximum dominant tumor size is 3 cm
and the tumor must be excised with negative surgical
margins at ink for invasive carcinoma and ≥ 2 mm negative
margins for DCIS or have a negative re-excision. The PBSI
should be deemed technically feasible based on the seroma
location, visibility, and size performing an ultrasound; the
total implanted volume should be < 150 cc. Patient should
have signed an informed consent.
Ineligible patients include those with lymphovascular
invasion, lobular features on histology (pure or mixed)
or sarcoma histology, triple negative tumors, extensive
in situ carcinoma, multicentric disease (in more than one
quadrant or separated by ≥ 2 cm), bilateral breast cancer,
recurrent breast cancer, Paget’s disease of the nipple, me-
tastases or active other cancer (defined by any malignancy
in < 5 years, excluding any cured non-melanoma skin can-
cer or cervical cancer), neoadjuvant chemotherapy, known
allergy for hyaluronic acid, active auto immune disorder
with severe vasculitis component, uncontrolled and com-
plicated insulin-dependent diabetes, pregnancy, cosmetic
breast implants, psychiatric or addictive disorder that
would preclude attending follow-up, or postoperative
wound infection or abscess following Centers for Disease
Control and prevention (CDC) criteria.
Interventions
The permanent seed implant procedure includes a com-
puted tomography (CT) simulation done positioning the
patient similarly to for external beam breast radiother-
apy. The clinical target volume (CTV) corresponds to
the seroma with a 1-cm margin, limited to the fascia
pectoralis, and 5 mm below the skin; the planned target
volume (PTV) is an additional expansion of 0.5 cm with
the same skin and chest wall limits. A pre-implant plan
is generated using the MIM Symphony® software (MIM
Software Inc., Cleveland, OH, USA) to order stranded
103Pd seeds of 2.5 U activity.
For the procedure, anesthesia includes a non-steroidal
anti-inflammatory drug (NSAID) for two days, light sed-
ation with Propofol, and local freezing. Patients are posi-
tioned on a breast board, with the arm abducted similarly
to the CT simulation. The breast skin is disinfected and the
patient draped. The PTV projection perpendicular to the
fiducial needle axis is outlined on the skin surface and
verified using ultrasound. A PBSI template (Concure
Oncology, Seattle, WA, USA) is attached to the fiducial
needle and immobilized using a modified medical articu-
lated arm (Fisso, Medtec Baitella Alt, Switzerland). The pre-
loaded needles containing 103Pd strands are then inserted
under US guidance [33]. In patients allocated to receive
spacer, an amount of 4–10 cc of biodegradable hyaluronic
acid (Barrigel™, Palette Life Sciences, Santa Barbara, CA,
USA or Restylane SubQ®, Galderma Benelux, Breda, the
Netherlands) is injected directly under the skin under ultra-
sound guidance covering the PTV projection, aiming to
create an extra 0.5–1 cm space between the treatment
volume and the skin. If the skin is judged not to be at risk
in all projection quadrants, it could be decided to only
inject the area at risk. The injected skin quadrants will be
reported specifically. All radiation oncologists involved in
this study are trained to perform the intervention and the
injection procedure and reporting instructions are incor-
porated in trial protocols. The hyaluronic acid spacer is
expected to be fully degraded after 3–9 months.
Outcomes
The primary endpoint of this trial is the occurrence of
telangiectasia at two years after PBSI. Assessment is
performed by a blinded physician, following the Bent-
zen’s 4-point scale which is included in the LENT/
SOMA questionnaire [34, 35]. This scale is defined as:
“none;” grade I, “< 1 cm2,” grade II, “1–4 cm2;” and
grade III, “> 4 cm2.” Patients will also be blinded for the
allocated treatment. The secondary outcomes include
the local recurrence rate at five and ten years, the
disease-free and overall survival rates at five years, as
well as brachytherapy and spacer injection adverse
events (AE) according to the commonly used NCI
Common Toxicity Criteria for Adverse Events (CTCAE
v 4.03) scale for acute side effects [36], practically oc-
curring within three months of the brachytherapy, and
the Radiation Therapy Oncology Group (RTOG)/ Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) scoring systems for late side effects [37], practic-
ally occurring after three months. The symptoms include
the experience of pain, skin redness, pigmentation, in-
duration, dermatitis, subcutaneous induration, and the
occurrence of infection at the site of spacer injection.
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Additionally, patient-reported outcome measures (PROMs)
include the cosmetic result with the Breast Cancer Treat-
ment Outcome Scale (BCTOS) questionnaire [38], using a
validated Dutch version which will shortly be published by
our group [39] and the health-related Quality of Life using
the Dutch version EORTC QLQ-C30 and BR23 question-
naires, version 3 [40]. Ipsilateral breast recurrence must be
proven getting a copy of the biopsy or the salvage surgery
pathology report. Dosimetry outcomes include the PTV
volumes receiving at least 100% or 200% of the prescribed
dose (V100 and V200) as quality assurance for all treatment
plans and maximum dose to a small skin volume of 2 mm
thickness over 1 cm2 (D0.2cc) [21, 41] and the presence of a
hotspot (isodose ≥ 90%) [42] on 1 cm2 of the skin as indica-
tors of skin toxicity risk.
Outcomes are collected before the PBSI implantation
at baseline, at the end of the procedure, and at two
months, six months, and every year up to five years, dur-
ing follow-up visits at the cancer center. If a patient does
not attend a follow-up appointment, she will be called
and/or her family doctor contacted. Reason for no-show
will be recorded in order to ensure exhaustive capture of
survival, recurrence, and/or AEs. Overall and disease-
specific survival will be assessed until 10 years through
GBA (Population registry, Gemeentelijke Basis Adminis-
tratie) and/or general practitioners. A summary of the
timing of questionnaires is detailed in Fig. 1.
Sample size
Previous studies found 22.4% telangiectasia at two years
[9]. We expect the use of a spacer could reduce the skin
dose to 50% [21] and the occurrence of any telangiectasia
(≥ grade 1) to 7.7% [43]. To test this reduction (e.g. the
superiority of the intervention), 105 (Fisher’s exact test)
patients per treatment arm would be needed (α = 0.05,
β = 0.20). A sample size of 230 patients will allow for a
10% lost to follow-up rate.
Recruitment
The Erasmus MC - Cancer Institute treats approxi-
mately 1000 patients with adjuvant breast radiotherapy
every year. Given the inclusion criteria, it is expected
that approximately 20% of these patients are eligible for
PBSI. On top of this, referrals from outside the area are
also expected specifically for PBSI. This makes it very
likely that the required sample size could be recruited in
three years.
Treatment allocation and blinding
After written informed consent and final eligibility check,
the radiation oncologist will enroll the patient and
randomization will be performed by the department’s in-
dependent trial manager. Patients will be randomly allo-
cated to one of the treatment arms (spacer injection or no
spacer injection) in a 1:1 allocation ratio, applying a vari-
able block size randomization (block sizes 2, 4, and 6).
This concealed allocation will be computer-generated
using the online randomization tool ALEA.
Patients will be blinded for the allocated treatment, as
the spacer injection is performed under sedation. How-
ever, in some cases the patient might see or feel the effect
of the spacer injection later. The treating radiation oncolo-
gist will be blinded during treatment planning and during
the implant of the palladium seeds and be unblinded after
the implant to inject the spacer or not using a telephone
call with the departments trial manager.
Investigators will be blinded for allocated treatment
during assessment of primary endpoint by performing
this assessment in a separate visit in which the physician
does not have access to the patient’s medical file.
Unblinding will be performed if a patient is going (un)-
planned off-study. In addition, in case of medical emer-
gencies possibly caused by the spacer, unblinding will be
performed. In these cases, a patient’s allocated treatment
can be unblinded by checking the medical record of the
implantation or by contacting the trial management.
Data management
Secure collection of data is performed. Data entry will
be performed using a predefined case report form (CRF)
(Additional file 2) with accompanied data entry protocol.
This provides instructions units to be used, missing data
handling and range checks.
Statistical methods
All statistical tests will be two-sided and a p value < 0.05
is considered to be significant. Statistical analyses will be
performed using IBM SPSS version 24 (IBM Corpor-
ation, Armonk, NY, USA). Data will be analyzed follow-
ing intention-to-treat and per-protocol. Missing data will
be handled using multiple imputation. Descriptive statis-
tics will be used for all outcome measures.
A Fisher’s exact test or Chi-squared test will be per-
formed to test the reduction in the rate of telangiectasia
in the study groups at two-year follow-up, i.e. to test the
hypothesis that the rates of telangiectasia in both study
groups are equal (superiority study).
Local recurrence-free survival as well as overall and
disease-specific survival rates at five and ten years will
be estimated using the Kaplan–Meier method. The local
recurrence rate will be reported at five and ten years. A
Fisher’s exact test or Chi-squared test will be performed
to test the difference in proportions (six-month, one-
year and two-year cumulative rate of side effects, skin
dose > 90% over at least 1 cm2 at post-planning) between
groups. (Skin) dosimetry data will be compared using a
Mann–Whitney U test or an unpaired Student’s t-test
depending of distribution of data. To study the effect of
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spacer on cosmesis (BCTOS questionnaire) and quality
of life (EORTC-QLQ-C30/BR23 and EQ5-D question-
naire) over time, a repeated measurements analysis will
be performed (linear mixed model, covariance structure:
unstructured) with independent variables time, allocated
group, and interaction effects between time and allo-
cated group.
Discussion
For early stage breast cancer patients that have out-
standing survival outcomes [3, 4], the role of radiother-
apy is essentially cosmetic [5]. The skin is a critical
structure in breast radiotherapy, with skin dose as the
main risk factor [21, 22]. In this study, we test an inter-
vention to reduce cosmetic impairment by aiming to
prevent long-term skin toxicity.
Telangiectasia are a specific marker of radiation toxicity
[21, 22]. Although rates are lower than with whole breast
irradiation, in breast brachytherapy 10–27% [9, 19, 24] of
the patients develop some grade of telangiectasia. Rates of
telangiectasia normally peak at two years till it stabilizes.
Most of the lesions are permanent resulting in decreased
quality of life [9]. Other skin toxicity scales (pigmentation,
induration, fibrosis) are less specific for capturing radi-
ation induced side effects [21].
Among our secondary outcomes are standard onco-
logical outcomes. Based on our pre-clinical study we do
not expect the spacer to influence the oncological effect-
ivity of PBSI. [44]. This work in mastectomy specimens
showed excellent feasibility of creating an extra 5-mm
space directly below the skin using a biodegradable spa-
cer. This space is not part of the PTV in LDR seed
Fig. 1 Schedule of enrolment, interventions, and assessments in this study
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brachytherapy as the CTV expansion is limited to 5 mm
below the skin by protocol [33]. The spacer partly lifted
the skin, but also moved the breast tissue inferior and
laterally. However, with the seeds already in place, we
expect that any change in PTV geometry will be similar
in the treated volume containing the seeds. This hypoth-
esis was supported by the excellent and comparable
PTV coverage (V100%) before and after injection in the
pre-clinical study [44]. However, this finding should be
confirmed in a clinical setting.
Other secondary outcomes are brachytherapy and spa-
cer injection AEs according to commonly used NCI
CTCAE and RTOG/EORTC scoring systems for late side
effects. Where our main hypothesis is that the spacer in-
creases distance and reduces skin dose and telangiecta-
sia, this will allow for analyzing the effect on other less
radiotherapy-specific symptoms such as pain, skin red-
ness, pigmentation, induration, dermatitis, subcutaneous
induration, and the occurrence of infection at the site of
spacer injection. Although hyaluronic acid is widely used
as a dermal filler, the application as a skin spacer in pa-
tients treated with breast radiotherapy is a new concept
and any unexpected side effects will be captured. Skin
dose outcomes will potentially lead to updated skin dose
constraints in treatment planning. Also, it could distin-
guish radiotherapy induced toxicity from other causes
(i.e. intervention-related toxicity). PROMs assess the ef-
fect of the skin spacer on cosmesis, function, and quality
of life. Furthermore, by using internationally recognized
PROMs, a better comparison with other radiotherapy
techniques is possible.
This clinical trial was designed because it is unknown
whether the dosimetric benefit of the spacer, which was
found in our pre-clinical study [44], translates in a real
patient benefit. An example of a clinical trial that could
not demonstrate that a dosimetric benefit translates into
better patient outcomes, is the breast intensity modu-
lated radiation therapy (IMRT) trial. In this trial, the im-
proved radiation dose distribution and reduced moist
desquamation using IMRT, compared to standard wedge
RT, did not result in reduced long-term side effects such
as chronic breast pain [43].
Our primary analysis will be done following the
intention-to-treat principle: the effect of skin spacer on
telangiectasia rate at two years. However, a per-protocol
analysis will allow for a better definition of a successful
skin spacer as the skin spacer injection protocol (> 5 mm
in a PTV skin projection area) is not definite and the trial
could be hypothesis-generating.
A drawback of our study is that we are not able to se-
cure a full double-blind design. Patients might be aware
of an injected spacer as it could be palpable under the
skin. For physicians, it might be possible to remember
the allocated treatment after being unblinded during the
PBSI procedure. However, with the assessment of the
primary outcome at two-year follow-up, this memory ef-
fect is not likely to cause any bias. Also, the type of out-
come measure (telangiectasia using Bentzen’s 4-point
scale) allows for an objective, reproducible assessment.
Furthermore, this a single-center study and our findings
should be confirmed in a multicenter setting. Lastly,
with only patients undergoing PBSI in this study, gene-
ralization of our findings to other APBI techniques
should be done with caution. However, theoretically, this
principle would hold for any APBI technique with a
rapid dose fall off.
In this trial, we investigate the effect of a subcutaneous
spacer injection on the skin dose, late skin toxicity, and
cosmetic outcome in patients treated with PBSI in the
setting of breast-conserving therapy. Our results will be
relevant for most forms of breast brachytherapy as well
as robotic radiosurgery, as skin spacers could be used to
protect the skin with these other techniques.
Trial status
Protocol version 5, 26 March 2018. The first patient was
enrolled in the study on 8 September 2017. Expected
completion of recruitment is at the end of 2020.
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Additional file 1: SPIRIT 2013 checklist. Recommended items to address
in a clinical trial protocol and related documents. (PDF 117 kb)
Additional file 2: CRF template. A predefined case report form provides
instructions units to be used, missing data handling and range checks.
(PDF 415 kb)
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